Navigation Links
Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
Date:11/27/2012

WESTFORD, Mass., Nov. 27, 2012 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that its senior management will present at the Canaccord Genuity Medical Technology & Diagnostics Forum at 10:30 a.m. (ET) on Tuesday, December 4 in New York City.

The presentation by Cynosure President and CEO Michael Davin and Executive Vice President, Treasurer and CFO Timothy Baker will be available via live and archived audio webcast accessible through a link on the Investor Relations section of the Company's website, www.cynosure.com.

About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.

Contact:

Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com 

 


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cynosure, Inc. Prices Public Offering of Class A Common Stock
2. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
3. Cynosure Announces Upcoming Conference Presentations
4. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
5. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
6. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
7. Scatter Radiation from Mammography Presents No Cancer Risk
8. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
10. Thoratec Presentation At Piper Jaffray 24th Annual Healthcare Conference To Be Webcast
11. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 1, 2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising ... novel investigational mda-7/IL-24 tumor,suppressor agent, in patients with ... were presented today at the,annual meeting of the ... 22-patient trial, INGN 241 induced killing in all ...
... Inc.,(TSX: TLN) announced today that preliminary data from ... cancer,patients was published in abstract form as part ... Meeting in Chicago,Illinois. In the Phase I dose ... two ovarian, one duodenal and one,glioma), that had ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... NY, April 17, 2014U.S. military personnel who served ... impact" concussive traumatic brain injury (TBI) were compared ... for other medical reasons. Differences in measures of ... 6-12 months after injury are reported in an ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2
... A short-term, very-high dose regimen of the immune-suppressing drug ... in most of a small group of patients studied ... disease, Johns Hopkins researchers report. The findings in nine ... suggest new ways to treat a disease that tends ...
... Bulge with Hoodia and Bitter Orange, LOS ... fatty,and unhealthy coffee creamers, Java Solutions today announces ... creamer to start your day off,with a weight-loss ... of,French vanilla and non-fat buttercream with Hoodia, a ...
... to Solantic Board, JACKSONVILLE, Fla., June 10 ... urgent care, today announced,the appointment of Tom Scully ... a General Partner with New York City Private ... largest private equity investor in,healthcare. In addition, Mr. ...
... 10 Christine Carson Filipovich, a,graduate of Venture ... Nursing Resources, Inc., was honored last month with ... Bolton School of Nursing at,Case Western Reserve University ... an alumna or alumnus "who has demonstrated,outstanding leadership ...
... no longer just for doctors as PointOne ... WAUWATOSA, Wis., June 10 PointOne Systems, ... tool, known as,RedBox Technology, will begin providing reports ... dramatic change from the industry,s focus,on hospitals, research ...
... Information technology has the power,"to transform data ... Co. executive Carly Fiorina once explained., ... Ingenious Med,s IM Quality,Measures(TM), a software package ... capture, report, and submit quality performance,metrics. Physicians ...
Cached Medicine News:Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 2Health News:'HiCy' drug regimen reverses ms symptoms in selected patients 3Health News:Leaner Coffee Creamer Boosts Metabolism and Curbs Appetite 2Health News:Healthcare Veteran Joins Solantic Board of Directors 2Health News:Nursing Entrepreneur Whose Business Career Was Spurred by Venture Training is Honored with Alumna Award from Case Western Reserve University 2Health News:PointOne Launches New Business Direction, Healthcare Analytics Beyond Hospitals 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 2Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 3Health News:Ingenious Med's IM Quality Measures(TM) Delivers Insight About Hospitalist Performance 4
Supplemental instrument to the Small Joint Arthroplasty System....
... System utilizes the same proven materials found ... The SR™ Hand Implant System provides advantages ... minimal bone resection, surface replacement of the ... and/or repositioning of the ligamentous soft tissues, ...
Anatomic implant shape and easy-to use instrumentation promote implant alignment, stability, and restored joint kinematics....
The NeurOptics Pupillometer is a portable instrument used to measure pupils to screen candidates for refractive procedures and other ophthalmic applications....
Medicine Products: